Journal Scans
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
PCV vs TMZ in Chemotherapy-Naïve Recurrent High-Grade Glioma
M Brada, S Stenning, R Gabe, LC Thompson, D Levy, R Rampling, S Erridge, F Saran, R Gattamaneni, K Hopkins, S Beall, VP Collins, S-M Lee
Yes
20100820
2010 Sept 20
J Clin Oncol
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
J Clin Oncol. 2010 Sept 20;[Epub Ahead of Print], M Brada, S Stenning, R Gabe, LC Thompson, D Levy, R Rampling, S Erridge, F Saran, R Gattamaneni, K Hopkins, S Beall, VP Collins, S-M Lee
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Treatment with concomitant temozolomide (TMZ) plus radiotherapy is the standard of care for patients with newly diagnosed glioblastoma multiforme (GBM). Studies have demonstrated the antitumor activity of TMZ in relapsed GBM and anaplastic astrocytoma (AA). However, no randomized study has compared TMZ with standard nitrosourea-based chemotherapy in this setting. In this study, Brada et al evaluated the use of TMZ versus procarbazine, lomustine, and vincristine (PCV) in patients with chemotherapy-naïve,...
